Track market-moving stories before they get noisy

Rep. Chip Roy, R-Texas, joins 'Mornings with Maria' to discuss President Donald Trump's push to tie the SAVE Act to FISA renewal and the Senate's struggle to advance key legislative priorities.

As of June 16, 2026, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Here's the latest list of major overbought players in this sector.

Corecivic Inc (NYSE:CXW)Hurco Companies Inc (NASDAQ:HURC)Geo Group Inc (NYSE:GEO)Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

On June 16, 2026, Root Inc ROOT shares rose 4.2% today, with the stock currently priced at $57.17. Over the past year, ROOT has experienced significant volatility, with a 52-week high of $143.04 and a low of $40.91.

GF Value™ verdict: Current price is $57.17, which is 35.4% below the GF Value™ estimate of $88.48. GF Score™: 73/100, indicating an above-average stock. Most notable signal: Insiders sold $0.8M in the last 3 months, with no buying activity. Is ROOT Overvalued or Undervalued? The current price of Root Inc ROOT at $57.17 is significantly lower than the GF Value™ estimate of $88.48, suggesting that the stock is undervalued by approximately 35.4%. This margin of safety indicates a potential opportunity for investors, as the GF Valuation label categorizes ROOT as significantly undervalued. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the undervaluation presents an opportunity, it is essential to consider potential risks associated with the stock. The YTD performance is down 20.9%, and the 1-year performance shows a steep decline of 60.7%. These figures may indicate underlying issues that could affect future performance, stressing the importance of due diligence.

How Does ROOT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 17.1x 24.7x Forward P/E 22.1x N/A Currently, ROOT's P/E (TTM) of 17.1x is significantly below its 5-year median P/E of 24.7x, indicating that the stock is trading at a lower valuation compared to its historical performance. The forward P/E of 22.1x suggests expectations of improvement in earnings, yet the current P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that ROOT is undervalued.

What Does ROOT's GF Score™ Tell Us? Metric Rating GF Score™ 73/100 Financial Strength 6/10 Profitability 4/10 Growth 8/10 Valuation 4/10 Momentum 5/10 The GF Score™ of 73/100 suggests that Root Inc ROOT has a favorable overall rating, with notable strengths in growth (8/10) and financial strength (6/10). However, the stock exhibits weaknesses in profitability (4/10) and valuation (4/10). This combination indicates potential for growth, but also highlights some concerns regarding its profitability and current valuation metrics.

What Are Insiders Doing with ROOT Stock? In the last three months, insiders have sold $0.8 million worth of ROOT stock, with no reported buying activity. This pattern of selling could indicate a lack of confidence among insiders regarding the stock's short-term prospects. The absence of insider buying further emphasizes caution, as it suggests that those with inside knowledge of the company are not currently optimistic about the stock's performance.

What This Means for Investors Based on the current analysis, Root Inc ROOT is considered undervalued according to the GF Value™ estimate. However, potential investors should take into account the recent insider selling and the stock's performance trends before making any decisions.

For the complete analysis, visit the Root Inc ROOT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is ROOT's GF Score™?

ROOT has a GF Score™ of 73/100, indicating it is an above-average stock with potential for higher long-term returns based on key factors.

Is ROOT overvalued or undervalued?

ROOT is undervalued, with a current price of $57.17 compared to a GF Value™ estimate of $88.48, suggesting a significant upside potential.

What is ROOT's P/E ratio?

ROOT has a P/E (TTM) ratio of 17.1x, which is 31% below its 5-year median P/E of 24.7x, further supporting the conclusion that the stock is undervalued.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Affirm Holdings (AFRM - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AFRM broke through the 20-day moving average, which suggests a short-term bullish trend.

The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages.

The 20-day moving average can show signals that are similar to other SMAs as well. If a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.

Over the past four weeks, AFRM has gained 11.6%. The company is currently ranked a Zacks Rank #3 (Hold), another strong indication the stock could move even higher.

The bullish case only gets stronger once investors take into account AFRM's positive earnings estimate revisions. There have been 10 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.

Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on AFRM for more gains in the near future.

LAKE MARY, Fla., June 16, 2026 (GLOBE NEWSWIRE) -- Spur Intelligence today announced new capabilities within Monocle Session Enrichment, enabling organizations of all sizes and maturity levels to gain new user session insights and accelerate their defensive efforts against growing anonymization threats.

As attackers increasingly rely on VPNs, residential proxies, mobile proxies, and other forms of traffic obfuscation, organizations need clearer ways to understand who is truly interacting with their applications and services. Recent Spur research found that only 30% of organizations fully understand the risks posed by anonymized IP activity, highlighting a significant visibility gap. The latest Monocle enhancements enable customers to move from visibility to action faster, adding granular service attribution and behavioral indicators that improve rules for smarter edge enforcement.

“Organizations know anonymized traffic is a growing challenge, but many still struggle to operationalize that intelligence,” said Alastair Parr, CTO of Spur. “These updates ensure that customers can implement inline enforcement in minutes, gain deeper visibility into user behavior, and quickly translate those insights into policy decisions that reduce risk.”

New Monocle Capabilities Help Teams Move From Visibility to Enforcement Faster

Designed to help organizations get more value from session enrichment, these enhancements make deployment faster, improve operational visibility, and provide greater control over how traffic intelligence is used across security, fraud, and trust workflows.

New capabilities include the following:

No-Code Cloudflare Integration Enables Inline Traffic Enforcement
Monocle now integrates directly with Cloudflare through a no-code deployment process that requires no engineering resources. Organizations can deploy Monocle inline with application traffic, configure where assessments are applied, and use policy decisions to allow or block requests in real time. A new monitor-only option also enables teams to evaluate traffic and refine policies before implementing enforcement actions. The Spur-Cloudflare integration makes inline traffic enforcement accessible without complex implementation, delivering value and a quick return on investment.

Advanced Analytics Improves Visibility Into User Sessions and Trends
New analytics capabilities deliver deeper visibility into user sessions, traffic composition, anonymous traffic types, policy decisions, geographic trends, and behavioral patterns. The centralized Explorer experience helps teams investigate activity, validate policies, and better interpret behavior and understand the impact of session enrichment across their environments.

Policy Builder Enables Granular Traffic Enforcement
New policy block strategies and configuration options enable organizations to auto-configure or customize traffic rules, including by traffic type, geography, or service. With this enhancement, security and fraud teams gain greater control over user sessions.

Streamlined Onboarding Ensures Faster Time to Value
A new guided onboarding workflow accelerates implementation with step-by-step setup instructions and documentation tailored to each deployment. Starting from the Platform home page, customers can activate Monocle faster, reduce onboarding friction, and begin generating actionable traffic insights sooner.

Helping Organizations Stay Ahead of Evolving Threats

As anonymization infrastructure becomes more accessible and attackers continue to find new ways to conceal their activity, organizations need solutions that are both powerful and practical to deploy.

With these latest enhancements, Spur makes session enrichment more accessible by eliminating implementation barriers, simplifying operational workflows, and delivering deeper insight into user behavior. The result is a faster path from traffic visibility to confident decision-making.

To learn more about Monocle and experience session enrichment firsthand, sign up for a free account at Spur Intelligence or visit the blog.

About Spur Intelligence

Spur delivers the highest-fidelity IP intelligence available to detect anonymized, proxied, or otherwise obscured internet traffic, empowering you to stop fraud, fake users, and threats. Designed by expert security researchers and engineers, Spur elevated VPN attribution, bot detection, and residential proxy tracking to protect the most mission-critical government and commercial systems in the world.

Media Contact:
Jennifer Tanner
Look Left Marketing
[email protected]

Frequently Asked Questions

What is session enrichment?

Session enrichment is the process of adding contextual intelligence to user sessions, helping organizations better understand who is interacting with their applications and services. By enriching sessions with infrastructure and IP intelligence, organizations can identify anonymized traffic, detect suspicious behavior, and make more informed security, fraud, and trust decisions.

Why is visibility into anonymized traffic important?

Attackers increasingly use anonymization services to conceal their identity, bypass controls, and blend in with legitimate users. Without visibility into these traffic sources, organizations may struggle to detect fraud, account abuse, bot activity, credential attacks, and other threats. Session enrichment provides the context needed to better understand user behavior and respond with greater confidence.

How does Monocle Session Enrichment help identify anonymized traffic?

Monocle analyzes user sessions using Spur’s IP intelligence to identify traffic originating from VPNs, residential proxies, mobile proxies, hosting providers, and other forms of traffic obfuscation. This additional context helps organizations distinguish legitimate users from potentially risky or deceptive activity.

How does the Monocle Cloudflare integration work?

The Monocle Cloudflare integration enables organizations to deploy session enrichment inline with application traffic through a no-code setup process. Once configured, Monocle can assess requests in real time and support policy-based decisions to allow, monitor, or block traffic based on customer-defined criteria.

What are the benefits of combining Cloudflare with IP intelligence?

Cloudflare helps organizations protect and manage internet-facing applications, while IP intelligence provides critical context about the source and characteristics of incoming traffic. By combining Cloudflare with Spur’s IP intelligence through Monocle Session Enrichment, organizations can gain deeper visibility into anonymized and high-risk traffic and apply policy decisions in real time. This enables security, fraud, and trust teams to more effectively detect suspicious activity, reduce abuse, and improve decision-making without adding operational complexity.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/986b50cf-1bf6-4fad-ae9d-fcabf51490c9

Spur Enhances Monocle Session Enrichment with No-Code Cloudflare Integration to Accelerate Inline Tr... The latest Monocle enhancements enable customers to move from visibility to action faster, adding gr...

© metamorworks / Shutterstock.com

Shares of CoreWeave (NASDAQ:CRWV) are up 10% in midday trading on Tuesday, with CoreWeave stock changing hands near $117. The move stands out sharply against the rest of the AI cloud group, which is slightly lower on the session.

For context, Cloudflare (NYSE:NET | NET Price Prediction) stock is down 2%, and Snowflake (NYSE:SNOW) stock is down 1%. So yes, on today’s scoreboard, CoreWeave stock is decisively outperforming its AI cloud peers.

The reason behind CoreWeave stock’s jump is clear: index mechanics. The catalyst evidently comes from a structural index change rather than a fundamental development.

NASDAQ 100 Inclusion Fuels the Bid The catalyst behind today’s surge in CoreWeave stock is the company’s official inclusion in the NASDAQ 100 index. Index inclusion mandates passive buying from funds that track the benchmark, creating forced demand independent of fundamentals.

That mechanical bid is layering on top of what’s already a story stock. CoreWeave reported Q1 2026 revenue of $2.08 billion, up 112% year over year, with a revenue backlog of $99.4 billion that includes a $21 billion Meta Platforms commitment. CEO Michael Intrator called it “the strongest bookings quarter in CoreWeave’s history.”

Reddit chatter around CoreWeave stock has also been steadily bullish, with sentiment scores in the 65 to 72 range across the past week. This reflects retail enthusiasm around the inclusion event.

Cloudflare and Snowflake: No Catalyst, No Bid The divergence is straightforward. Cloudflare and Snowflake have no company-specific news today, and both are drifting modestly lower in a market that’s rotating toward the AI infrastructure pure-play.

Cloudflare’s fundamentals remain solid. The company’s Q1 2026 revenue came in at $639.75 million, up 34% year over year, and CEO Matthew Prince described AI as “the biggest tailwind we’ve ever seen in Cloudflare’s history.” Cloudflare stock is still up 18% year to date.

Snowflake’s last quarterly print was also strong, with Q1 FY2027 revenue of $1.39 billion, up 34% year over year, and a raised FY2027 product revenue guide to $5.84 billion. Snowflake stock is up 9% year to date. Neither name simply has a fresh trigger today.

The Scoreboard Year to Date Stepping back from the single session, CoreWeave stock is up 64% year to date, well ahead of both peers. The pure-play GPU cloud thesis is clearly winning the AI-infrastructure trade in 2026 so far.

That said, a one-day pop driven by index-inclusion mechanics is not the same as a durable thesis shift. CoreWeave is a relatively newly public, volatile name. The same Q1 print that showed triple-digit growth also revealed a net loss of $740 million and capital expenditures of $7.7 billion in a single quarter.

Analyst consensus on CoreWeave stock currently sits at a $140.18 target with 22 buy, 11 hold, and 2 sell ratings. So there’s still room above current levels, but the path will likely be choppy.

What to Watch Next Investors can watch for whether passive flows continue to support CoreWeave stock through the official rebalance window, and whether the gains hold into the close. Index inclusion typically creates a short burst of demand, and the question is what happens once that mechanical bid fades.

For Cloudflare and Snowflake, the next real catalysts are likely to be their respective Q2 prints. Until then, expect both to trade with the broader cloud sector rather than on company-specific news. Investors holding the group can keep their position sizes modest, since AI-infrastructure names like CoreWeave stock can move quickly in either direction.

SUNNYVALE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced the availability of FortiSOC, a unified, cloud-delivered security operations center (SOC) platform. FortiSOC brings together six security operations functions into a single Software-as-a-Service (SaaS) experience and embeds agentic AI to autonomously investigate and correlate alerts across assets and identities, then recommend or execute response actions under analyst oversight. Built on Fortinet’s proven security operations (SecOps) technologies, FortiSOC helps organizations simplify and scale modern operations through one console, one subscription, and one unified operating model.

“Security teams today are being challenged by faster attacks, growing investigation volume, and fragmented operations that simply don’t scale,” said Michael Xie Founder, President, and Chief Technology Officer at Fortinet. “FortiSOC gives organizations a simpler way to operationalize the SOC capabilities they need through a unified, cloud-delivered platform designed to support security teams of all sizes, from teams building foundational capabilities to enterprises scaling advanced SOC environments. With embedded AI, integrated workflows, and built-in best practices informed by Fortinet’s own global security operations center, FortiSOC delivers the power of an AI SOC to help customers eliminate complexity, automate threat detection and response, and stay a step ahead of attackers.”

One Unified Platform for Modern Security Operations
FortiSOC is designed to simplify how organizations operationalize security operations by unifying security information and event management (SIEM); security orchestration, automation, and response (SOAR); threat intelligence; and behavioral and identity threat detection (ITDR) into a single platform. With agentic AI and FortiGuard Labs threat intelligence, FortiSOC extends the SecOps innovations introduced at Fortinet Accelerate 2026 by integrating analytics, investigation, automation, and response workflows into a single cloud-delivered experience for modern environments. FortiSOC enables security teams to move from alert to investigation to response with reduced friction, fewer operational silos, and stronger cross-environment visibility.

Support for Every Stage of the SOC Journey
FortiSOC is designed to support organizations at every stage of SecOps adoption, from resource-constrained teams establishing foundational monitoring capabilities to highly sophisticated and advanced SOC teams requiring deeper automation, broader correlation, and AI-assisted investigation at scale.

Based on proven Fortinet technologies, FortiSOC extends this journey through a cloud-delivered approach that combines advanced cyber defense, essential network operations center (NOC) and IT visibility, and adaptable workflows that can expand with customer needs. Organizations can use it to establish a streamlined entry into SecOps, modernize legacy approaches, or scale large or mature environments without changing direction as requirements evolve.

FortiAI-Assist further differentiates FortiSOC by applying autonomous investigation, AI-generated playbooks, and Model Context Protocol (MCP)-powered agent coordination across alerts, investigations, threat hunting, cases, and response actions. Leveraging enterprise-wide telemetry and threat intelligence, FortiAI-Assist helps coordinate activity across tools, workflows, and teams within the same platform. Security teams can tailor processes, coordinate activity across security and IT systems, involve stakeholders across departments, and extend use cases over time while maintaining the speed, consistency, and control required in modern environments.

Key benefits include:

One platform, total control: Unify SIEM, SOAR, user and entity behavior analytics (UEBA), case management, threat intelligence, ITDR, and AI-driven operations into a single SaaS platform. FortiSOC gives security teams the speed of AI, consistency, and clarity to stay ahead of threats without the overhead of managing multiple tools.One subscription, zero complexity, better ROI: A single console and subscription model helps reduce procurement complexity, streamline day-to-day operations, and improve resource allocation so security teams can focus on the most important objective: stopping threats.Ready on day one, prepared for what comes next: Best-practice content for detection methods, playbooks, and more based on Fortinet’s own global SOC operations are available out-of-the-box. FortiGuard Labs real-time threat intelligence, outbreak alerts, and monthly content updates allow organizations to keep pace with the speed and sophistication of today’s threat actors.Connected by design, ready to scale: Native integrations across the entire Fortinet Security Fabric and thousands of third-party connectors eliminate coverage gaps and help organizations automate detection and response across security, IT, and business systems. MCP support extends this reach to diverse environments, allowing FortiAI-Assist to operate, orchestrate, and coordinate various AI capabilities and tasks throughout FortiSOC, minimizing manual handoffs that slow remediation. Extending the Fortinet SOC Platform
FortiSOC complements and expands the broader Fortinet SOC Platform portfolio of FortiAnalyzer, FortiSIEM, and FortiSOAR by uniting and extending these capabilities for customers who prefer a single cloud-based SOC platform model. These existing best-of-breed solutions will continue to be enhanced and available. Together, these solutions comprise the Fortinet SOC Platform, which delivers flexible pathways and purchase options tailored to meet customer needs today and offering them a smooth pathway for future evolution.

As organizations modernize SecOps, analysts continue to see growing demand for integrated, cloud-delivered SOC platforms that simplify operations and reduce tool sprawl.

“IDC research shows that organizations are increasingly prioritizing analyst workflow and investigation experience as well as cloud-delivered security operations as they work to improve visibility, streamline processes, and accelerate response,” said Michelle Abraham, Senior Research Director, Security and Trust, IDC. “FortiSOC builds on Fortinet’s established security operations portfolio by combining proven technologies into a unified SaaS platform that can support both foundational and advanced SOC use cases.”

Read the blog and listen to the webinar for more detail on how FortiSOC helps streamline SecOps and accelerate detection and response.

Additional Resources

Learn about FortiSOC.Read more about the Fortinet Security Fabric.Learn about the Fortinet Open Ecosystem.Visit fortinet.com/trust to learn about Fortinet innovation, collaboration partners, product security processes, and enterprise-grade products.Read about how Fortinet customers are securing their organizations.Learn about Fortinet’s commitment to product security and integrity, including its responsible product development and vulnerability disclosure approach and policies.Follow Fortinet on X, LinkedIn, Facebook, and Instagram. Subscribe to Fortinet on our blog or YouTube. Copyright© 2026 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAIOps, FortiAgent, FortiAntenna, FortiAP, FortiAPCam, FortiAuthenticator, FortiCache, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCentral, FortiCNP, FortiConnect, FortiController, FortiConverter, FortiCSPM, FortiCWP, FortiDAST, FortiDB, FortiDDoS, FortiDeceptor, FortiDeploy, FortiDevSec, FortiDLP, FortiEdge, FortiEDR, FortiExplorer, FortiExtender, FortiFirewall, FortiFlex FortiFone, FortiGSLB, FortiGuest, FortiHypervisor, FortiInsight, FortiIsolator, FortiLAN, FortiLink, FortiMonitor, FortiNAC, FortiNDR, FortiPAM, FortiPenTest, FortiPhish, FortiPoint, FortiPolicy, FortiPortal, FortiPresence, FortiProxy, FortiRecon, FortiRecorder, FortiSASE, FortiScanner, FortiSDNConnector, FortiSIEM, FortiSMS, FortiSOAR, FortiSRA, FortiStack, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLM, FortiXDR and Lacework FortiCNAPP.

Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Let's take a look at what these Wall Street heavyweights have to say about Cameco (CCJ - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Cameco currently has an average brokerage recommendation (ABR) of 1.53, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 19 brokerage firms. An ABR of 1.53 approximates between Strong Buy and Buy.

Of the 19 recommendations that derive the current ABR, 12 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 63.2% and 21.1% of all recommendations.

Brokerage Recommendation Trends for CCJ

Check price target & stock forecast for Cameco here>>>

The ABR suggests buying Cameco, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in CCJ?Looking at the earnings estimate revisions for Cameco, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $1.32.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Cameco. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Cameco.

© Michail Petrov / Shutterstock.com

The bear case on McCormick (NYSE:MKC | MKC Price Prediction) had been a familiar story of input-cost pressure and a sluggish retail backdrop. That story changed when management announced the $44.8 billion merger with Unilever‘s (NYSE:UL) food business, layered on top of the January 75% controlling stake in McCormick de Mexico. For income investors, the question is whether a deal this large threatens the dividend. I think it strengthens it.

Dividend Snapshot Metric Value Annual Dividend $1.92 per share Dividend Yield (at $47.87) ~4.0% Consecutive Annual Increases 40 years Most Recent Increase 7% (November 2025) Aristocrat / King Status Aristocrat (not yet King) Payout Ratios Leave Real Breathing Room McCormick paid $483 million in dividends against FY2025 free cash flow of roughly $740.4 million ($962.2M operating cash flow less $221.8M capex). On EPS of $3.00, the $1.92 dividend takes 64% of profits.

Metric TTM Value Assessment Earnings Payout 64% Healthy FCF Payout 65% Healthy OCF / Dividend Coverage 1.99x Adequate Debt Climbed, but the Balance Sheet Still Stands The McCormick de Mexico close pushed total liabilities to $8.79 billion against $7.56 billion of equity, a debt-to-equity ratio of roughly 1.16. The Unilever Foods transaction will lift net leverage to at or below 4x at close, with management targeting roughly 3x within two years. Elevated for now, but with a clear path down. Flavor demand is inelastic, which is exactly why food represented 7.11% of total PCE in April 2026, almost unchanged across 16 months of data.

40 Years of Increases, and Resilience Through Two Crises The quarterly dividend stepped from $0.42 (2024) to $0.45 (2025) to $0.48 (late 2025). The payout held and grew through both the 2008 crisis and the 2020 pandemic, with no cuts on record.

Management Effectively Pre-Committed to the Payout On the merger call, CFO Marcos Gabriel said the combined company will support “McCormick’s long-standing practice of returning capital to shareholders through dividends” at a payout ratio of “approximately 60%”. CEO Brendan Foley added that “our commitment to returning cash to shareholders through dividends remains unchanged.” The deal targets $600 million in synergies and is accretive in year one across all P&L lines.

Verdict: Safe, With Leverage Worth Watching Dividend Safety Rating: Safe. A 64% earnings payout, 65% FCF payout, 1.99x cash coverage, and a 40-year streak give the $1.92 dividend a real margin of safety, even as the stock sits 33.42% below last year. The income thesis holds together if the company executes its 3x net leverage target on schedule and synergies arrive as guided. The thesis weakens if FCF stays compressed beyond 2027 or if integration costs push the FCF payout above 90%. For now, this Aristocrat keeps its income credentials intact.

T. Rowe Price remains a Strong Buy, with a compelling risk-reward profile and a valuation reflecting conservative assumptions despite macro potential improvements. TROW boasts a pristine balance sheet, with zero financial debt, $3.73B in cash, and robust free cash flow, supporting sustainable dividends, aggressive buybacks, and potential M&A activity. Recent AUM growth, strong equity/multi-asset fund performance, and an attractive yield underpin TROW's resilience, even as net retail outflows persist.

Key Takeaways EXPD shares rose 43.4% in a year, outperforming the industry's 21.9% growth. Expeditors benefits from e-commerce growth driving demand for global logistics services. EXPD saw 2026 and 2027 consensus estimates revised 10.1% and 4.3% higher. Expeditors International of Washington (EXPD - Free Report) shares have performed impressively on the bourse of late. Shares of this Seattle, WA-based company have surged 43.4% over the past year, outperforming the Zacks Transportation - Services industry’s 21.9% growth.

Image Source: Zacks Investment Research

Given the impressive price performance, let's take a deeper look at the factors driving growth at this leading third-party logistics (3PL) provider, which currently sports a Zacks Rank #1 (Strong Buy), and assess its potential for continued gains.

The continued expansion of e-commerce remains a favorable tailwind for Expeditors. As online retailers and consumers increasingly demand faster, more reliable deliveries, the need for efficient global logistics solutions has intensified. This trend supports demand for intermodal transportation, where goods are moved seamlessly across ships, railways and trucks. This allows Expeditors to leverage its extensive freight forwarding network and expertise in managing complex supply chains. Sustained e-commerce activity should therefore continue to create opportunities for volume growth and service expansion.

The company's strong balance sheet further enhances its long-term growth prospects by providing the flexibility to pursue strategic acquisitions and invest in its operations without placing undue strain on its finances. Its disciplined approach to capital allocation enables the company to capitalize on growth opportunities while maintaining financial resilience amid changing market conditions.

Moreover, EXPD's commitment to returning capital to shareholders through dividends and share repurchases reflects management's confidence in its cash-generating ability. These shareholder-friendly initiatives not only enhance investor returns but also reinforce market confidence in Expeditors' ability to balance growth investments with shareholder rewards, supporting its overall investment appeal.

Estimate Revisions to Head NorthDriven by the positives discussed above, the Zacks Consensus Estimate for the full-year 2026 and 2027 has been revised 10.1% and 4.3%, respectively, upward over the past 60 days.

Other Stocks to ConsiderInvestors interested in the Zacks Transportation sector may consider Star Bulk Carriers Corp. (SBLK - Free Report) and Teekay Tankers Ltd (TNK - Free Report) . 

SBLK currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Star Bulk Carriers has an expected earnings growth rate of more than 100% for the current year.  The company has an encouraging earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and met once in the remaining, delivering an average beat of 75.3%.

Teekay Tankers Ltd currently sports a Zacks Rank #1.

TNK has an expected earnings growth rate of 98% for the current year. The company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 10.2%.

Expeditors International of Washington, Inc. (EXPD) Discusses Geopolitical Risks and Trade Tensions Impacting Europe, Russia, US, and China Transcript

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ: LCID) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-05128, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lucid securities between February 25, 2026 and April 13, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Lucid securities during the Class Period, you have until July 28, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Lucid is a technology company that designs, develops, manufactures, and sells electric vehicles, EV powertrains, and battery systems. The Company’s products include, inter alia, the “Lucid Air” sedan and “Lucid Gravity” sport utility vehicle.

At all relevant times, Defendants touted purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations. In particular, beginning in late-February 2026, Defendants represented that, in fiscal year (“FY”) 2025, they had implemented sustainable improvements in these areas, including with respect to the production and ramp-up of deliveries of the Lucid Gravity. Defendants likewise asserted that these improvements would lead to profitable growth and performance efficiencies in FY 2026. Unbeknownst to investors, however, Lucid’s performance was materially hampered by significant supplier and delivery issues in February 2026, putting the Company on track for dismal, rather than improved, performance in its first quarter (“Q1”) of 2026.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company’s business and financial results; (iii) accordingly, the Defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The truth began to emerge on April 3, 2026, when Lucid issued a press release “announc[ing its Q1 2026] production and delivery totals[.]” Lucid revealed that it had “produced 5,500 vehicles” during Q1 2026, while only “deliver[ing] 3,093 vehicles.” The press release further disclosed that, “[d]uring the quarter, deliveries of the Lucid Gravity were disrupted for 29 days due to a supplier quality issue with the second-row seats” and, “[a]s a result of this, the company’s ability to meet customer demand was impacted.”

The same day, Reuters published an article entitled “Lucid misses first-quarter vehicle delivery estimates on supplier disruptions”. The article provided additional color and comments from Defendant Marc Winterhoff (“Winterhoff”), the Company’s Interim Chief Executive Officer (“CEO”), regarding Lucid’s disappointing Q1 2026 delivery results—most notably that deliveries were particularly impacted over a month earlier in February 2026, when Lucid paused to reverse an unauthorized supplier change and inspect vehicles already produced.

The next trading day, April 6, 2026, 24/7 Wall St. published an article entitled “Lucid Faces Biggest Disaster Ever”, which described the number of vehicles that Lucid delivered in Q1 2026 as “remarkably small”, stating that Lucid “cannot sell fewer than 4,000 vehicles and even pretend this is sustainable.” 

Following the foregoing news and disclosures, Lucid’s stock price fell $1.13 per share, or 11.35%, over the following two trading sessions, to close at $8.83 per share on April 7, 2026.

On April 14, 2026, Lucid filed a current report on Form 8-K with the United States Securities and Exchange Commission (“U.S.”), reporting, inter alia, its preliminary Q1 2026 financial results, including revenue in the range of $280 million to $284 million—well below the consensus estimate of $433.8 million—and losses from operations in the range of $985 million to $1.005 billion.

The same day, Lucid issued a press release revealing its plans for a $1.05 billion capital raise, including a $300 million public stock offering.

Following these disclosures, Lucid’s stock price fell $0.44 per share, or 4.76%, to close at $8.80 per share on April 14, 2026.

Then, on May 5, 2026, Lucid issued a press release reporting its Q1 2026 financial results, including GAAP earnings per share of -$3.46, missing consensus estimates by $0.83, a net loss of over $1 billion, and revenue of $282.47 million, missing consensus estimates by $76.04 million. Defendant Winterhoff, as quoted in the press release, acknowledged that the previously disclosed “supplier issue . . . during the quarter had an impact,” and the need to “align[] production and delivery with customer demand.” Lucid’s Chief Financial Officer, Defendant Taoufiq Boussaid, as quoted in the same press release, likewise acknowledged that “[w]e ended the quarter with elevated inventory that we expect to convert to revenue and cash as deliveries normalize[.]”

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

In the latest close session, Lucid Group (LCID - Free Report) was down 4.38% at $5.02. This change lagged the S&P 500's 0.57% loss on the day. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.

Shares of the an electric vehicle automaker witnessed a loss of 8.38% over the previous month, trailing the performance of the Auto-Tires-Trucks sector with its loss of 0.94%, and the S&P 500's gain of 2.14%.

The upcoming earnings release of Lucid Group will be of great interest to investors. On that day, Lucid Group is projected to report earnings of -$2.54 per share, which would represent year-over-year growth of 9.29%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $373.56 million, up 43.99% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$10.75 per share and revenue of $2.18 billion, indicating changes of +11.08% and +60.83%, respectively, compared to the previous year.

It is also important to note the recent changes to analyst estimates for Lucid Group. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Lucid Group is currently a Zacks Rank #4 (Sell).

The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Issued on behalf of Conexeu Sciences Inc.

A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.

, /PRNewswire/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 15, 2026, Conexeu Sciences Inc. (Nasdaq: CNXU), a preclinical-stage regenerative-tissue company that began trading only weeks earlier, offered a revealing answer: it expanded its board from six to nine directors, promoted a co-founder to Chief Commercial Officer, and added a prominent aesthetics-industry figure to its advisory board — five appointments in all, weighted heavily toward Fortune 500 finance, capital-markets, and commercialization experience.

The move is less about any single hire than about what the collective résumé signals. For a company whose lead technology is still preclinical, building a board stocked with big-company financial and operating discipline is a statement of intent: that Conexeu means to be judged not as a science project, but as a company on a path to commercialization in one of the most consequential frontiers in medicine — helping the body regenerate its own tissue. Whether it can deliver on that intent remains years from resolution, but the governance build-out is the kind of step investors in early-stage medtech tend to watch closely.

Key Takeaways

Board expanded from six to nine: Conexeu appointed Ana Bastiani-Posner, April Burke, and Andrew Costa as new directors, deepening its bench across healthcare finance, capital markets, M&A, and growth equity. A commercialization signal: Co-founder and director David Bogart was named Chief Commercial Officer to lead commercial strategy and operations, having helped shape the company's platform and regulatory pathway from inception. An aesthetics heavyweight on advisory: Melinda Farina, known as "The Beauty Broker" and founder of Integrated Aesthetics Consulting and Beauty Brokers Inc., joined the advisory board, reinforcing Conexeu's push into the aesthetics market. Pedigree that stands out: The new directors bring senior roles from Kyowa Kirin, Allergan, Novartis, Schering-Plough, Lucid Hearing, RX3 Growth Partners (the consumer growth-equity firm co-founded by NFL quarterback Aaron Rodgers), Morgan Stanley, and J.P. Morgan. Context — momentum and risk: The appointments follow Conexeu's May 2026 Nasdaq listing and June bell-ringing, as it advances its preclinical CXU™ platform toward a targeted early-2027 FDA 510(k) submission — a milestone, not a guarantee. Who Conexeu Just Brought In

The headline additions are notable for their financial and operating heft. Ana Bastiani-Posner, named chair of the Compensation Committee and a member of the Audit Committee, is a C-suite executive with more than two decades of leadership across Fortune 500 companies; she currently serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, where she helps oversee roughly $1.2 billion in annual revenue, and has held senior roles at Allergan, the New York Genome Center, Schering-Plough, and Novartis. April Burke, joining the Audit and Compensation Committees, is Executive Vice President and CFO of Lucid Hearing, with expertise spanning public companies, private-equity-backed organizations, capital allocation, M&A, and IPO readiness.

Andrew Costa, named chair of the Audit Committee, rounds out the new directors as an investor and growth-equity operator with fifteen years across private equity, investment banking, and military leadership. He is Co-Managing Partner of RX3 Growth Partners — the consumer-focused growth-equity firm co-founded by NFL quarterback Aaron Rodgers, investing in health, wellness, and active-lifestyle brands, where he sits on boards including Therabody — and previously held investment-banking roles at Morgan Stanley and J.P. Morgan, after serving as a Captain in the U.S. Air Force. Alongside the board additions, co-founder and director David Bogart was elevated to Chief Commercial Officer; a capital-markets and investor-relations strategist who has advised on more than $75 million in capital formation, Bogart has helped shape Conexeu's IP and regulatory strategy since inception. And on the advisory side, Melinda Farina — "The Beauty Broker," with nearly three decades in medical aesthetics — brings consumer-health, brand-development, and market-positioning expertise directly relevant to Conexeu's aesthetics ambitions.

"Conexeu is entering an exciting new phase of growth, and it is important that our leadership team reflects the breadth of expertise needed to support both our scientific vision and business strategy," said Miles Harrison, CEO and President of Conexeu Sciences, adding that he looked forward to working with Bogart to "build our commercial foundation, expand our pipeline, and position Conexeu for scalable growth."

What the Company Is Actually Building

The leadership news only matters because of what sits beneath it. Conexeu is a preclinical-stage regenerative-tissue company built around a proprietary bioregenerative extracellular matrix platform it calls CXU™. The extracellular matrix is the natural scaffolding that surrounds cells in the body, providing the structural and biochemical cues that tell cells where to go and how to rebuild. Conexeu's lead device candidate, Ten-Minute Tissue™, is a thermosensitive ECM engineered to remain fluid at room temperature and then transition into a stable gel scaffold in place, at body temperature, within roughly ten minutes — a property designed to let it conform to and fill the irregular, three-dimensional geometry of real wounds and soft-tissue defects that flat sheets and powders struggle to address.

The company frames its strategy with a deliberately simple refrain — "one formula, one device" — a single platform engineered to scale across multiple billion-dollar markets rather than the traditional one-molecule, one-indication model. Those target markets include advanced wound care, periodontal applications, and facial and body contouring (including the soft-tissue laxity associated with rapid GLP-1-driven weight loss), with longer-term expansion into 3D printing and biofabrication and even veterinary medicine. Conexeu has also unveiled a 3D-bioprinted regenerative breast matrix program, branded B.R.E.A.S.T.™, in preclinical development with the Wake Forest Institute for Regenerative Medicine, aimed at moving breast reconstruction beyond implants toward true tissue regeneration. The platform rests on more than a decade of university preclinical research and is protected by issued patents across the U.S., E.U., Japan, and Australia, with Conexeu holding full rights and no royalty obligations. Management is pursuing a predicate-based U.S. regulatory route, with a 510(k) submission for its initial wound-care indication targeted for early 2027.

A Sector With Powerful Tailwinds — and Heavyweight Players

Conexeu is wading into a field with genuine momentum. The shift from simply replacing or covering damaged tissue toward actively regenerating it spans several large, growing markets — advanced wound care, medical aesthetics and body contouring, and surgical reconstruction — all propelled by aging populations, the diabetes epidemic, and, increasingly, the GLP-1 weight-loss wave and the soft-tissue changes that follow it. To understand both the scale of the opportunity and the competition, it helps to look at the established public companies operating across the markets Conexeu is targeting. They are far larger, commercial, and more diversified, which makes them useful reference points rather than direct equivalents.

Smith+Nephew plc (NYSE: SNN) is one of the clearest reference points for the wound-care and tissue-repair side of Conexeu's platform. A global medical-technology company explicitly focused on the repair, regeneration, and replacement of soft and hard tissue, Smith+Nephew operates a leading advanced wound management business and bioinductive regenerative implants. It illustrates the scale and breadth a tissue-technology franchise can reach — and the entrenched, well-capitalized competition any newcomer in regenerative wound care must eventually reckon with.

AbbVie Inc. (NYSE: ABBV) anchors the aesthetics comparison through its Allergan Aesthetics division, the dominant force in medical aesthetics with a multibillion-dollar franchise spanning injectables and body contouring. AbbVie has been actively addressing the aesthetic consequences of GLP-1-driven weight loss — precisely the soft-tissue laxity Conexeu is targeting — making it a powerful illustration of how large the aesthetics opportunity is, and how formidable the incumbent is in the market Conexeu hopes to enter with a regenerative approach.

Establishment Labs Holdings Inc. (Nasdaq: ESTA) is perhaps the most thematically precise comparison for Conexeu's breast program. A pure-play breast-aesthetics-and-reconstruction company built around its Motiva implants and tissue-expander technologies, Establishment Labs has grown into a company with more than $200 million in annual revenue. As Conexeu advances its B.R.E.A.S.T.™ bioprinted matrix toward a regenerative alternative to implant-based reconstruction, Establishment Labs represents both the established approach Conexeu aims to leapfrog and the commercial scale a focused breast-health franchise can achieve.

Stryker Corporation (NYSE: SYK) rounds out the group as one of the largest and most respected medical-technology companies in the world, with a substantial presence in wound care, regenerative and reconstructive products, and surgical solutions. Stryker exemplifies the diversified, large-cap medtech model and the commercialization machinery — sales, regulatory, and distribution muscle — that turns medical innovation into durable revenue. It is the kind of established player whose scale a platform company like Conexeu would aspire to over the long term. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they are vastly larger, commercial-stage, and more diversified than Conexeu, which is an early-stage, preclinical company.

The Risks Behind the Promise

It is essential to keep Conexeu's stage of development front and center. This is a preclinical-stage company; its CXU™ platform is an investigational device candidate whose safety and effectiveness have not been established and which has not been reviewed or cleared by the FDA. The company's own disclosures caution that preclinical findings from laboratory and animal models may not predict human results, that its planned early-2027 510(k) submission may slip or face additional FDA data requests, and that marketing clearance may be delayed, limited, or never granted. A strong board does not change the fundamental reality that the science must still be proven in the regulatory arena.

There are commercial and financial risks as well. As a newly public, development-stage company in a capital-intensive field, Conexeu will need continued access to financing to fund the long road from preclinical work through manufacturing, regulatory testing, and commercialization — a path most product candidates never complete. It faces enormous, well-funded competition from the very kinds of companies referenced above, and the predicate-based 510(k) route, while potentially faster, does not remove the inherent uncertainty of medical-device development. Investors should weigh the genuine credibility a strengthened board lends against the substantial execution risk that remains.

Why It Still Matters

For all those caveats, the logic behind Conexeu's leadership build-out is sound, and the trajectory of its field is unmistakable. Regenerative medicine is moving from a scientific aspiration toward a commercial reality, propelled by demographic and metabolic trends that are only intensifying — an aging world, a diabetes epidemic, a GLP-1 boom reshaping the aesthetics landscape, and a broad shift from replacing tissue toward rebuilding it. Bringing in directors and executives who have operated at the scale of Kyowa Kirin, Allergan, Novartis, and the major investment banks is precisely how an early-stage company signals it intends to compete in that future rather than merely research it.

Whether Conexeu converts that intent into cleared products and durable revenue will be decided over years, in manufacturing suites and regulatory reviews, not in board announcements. But the company is assembling the pieces — a differentiated platform, a multi-market strategy, and now a leadership team built for commercialization — to pursue one of the most compelling questions in modern medicine: not how to replace what the body has lost, but how to help it rebuild. For investors tracking where regenerative medicine is headed, Conexeu's post-listing moves are a small but telling marker of a company positioning itself for the long game.

CONTINUED … Learn more about Conexeu Sciences Inc. at: https://www.conexeu.com

SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVES

Eagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.

Explore Eagle Eye free (for now) at https://Eagle-Eye.dev

CONTACT:

American News Group

[email protected]

SOURCES:

[1] Conexeu Sciences Inc. — "Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing" (June 15, 2026; primary source for the board expansion, appointee bios, committee assignments, CXU™/Ten-Minute Tissue™ platform, and CEO Miles Harrison quote):

https://www.conexeu.com/resources/conexeu-expands-board-executive-and-advisory-leadership-with-five-appointments-post-nasdaq-listing

[2] Conexeu Sciences Inc. — "Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol 'CNXU'" (May 21, 2026; Nasdaq listing, platform overview):

https://www.conexeu.com/resources/conexeu-sciences-commences-trading-on-nasdaq-under-ticker-symbol-cnxu

[3] Conexeu Sciences Inc. — "Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program" (June 8, 2026; Q1 2027 510(k) plan, CDMO transfer, Ten-Minute Tissue™):

https://www.conexeu.com/resources/conexeu-sciences-reports-manufacturing-scale-up-and-regulatory-progress-for-lead-cxu-tm-wound-care-program

[4] Conexeu Sciences Inc. — "Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine" (May 27, 2026):

https://www.conexeu.com/resources/conexeu-sciences-initiates-preclinical-development-program-for-b-r-e-a-s-t-tm-bioregenerative-matrix-platform-with-wake-forest-institute-for-regenerative-medicine

[5] Establishment Labs Holdings Inc. — FY2025 results and company profile (NASDAQ: ESTA; breast aesthetics & reconstruction, Motiva, ~$211M 2025 revenue; sector/peer context with SNN, ABBV, SYK):

https://stockanalysis.com/stocks/esta/

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

American News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by American News Group on behalf of MIQ. MIQ has been paid a fee for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQ does not own shares of Conexeu Sciences Inc. but reserves the right to buy and sell shares of Conexeu Sciences Inc. at any time without any further notice. There may be 3rd parties who may have shares of Conexeu Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of Conexeu Sciences Inc. by CDMG; this is a digital media distribution.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. Forward-looking statements regarding leadership, preclinical and clinical development, manufacturing, regulatory submissions and clearances (including the planned first-quarter 2027 510(k) submission), reimbursement, market size, and commercialization are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

DraftKings (DKNG - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this company have returned +11.7%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Gaming industry, which DraftKings falls in, has gained 3.9%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, DraftKings is expected to post earnings of $0.34 per share, indicating a change of -10.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -7.3% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $1.15 points to a change of +74.2% from the prior year. Over the last 30 days, this estimate has changed -2.8%.

For the next fiscal year, the consensus earnings estimate of $1.78 indicates a change of +54.4% from what DraftKings is expected to report a year ago. Over the past month, the estimate has changed -1.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for DraftKings.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For DraftKings, the consensus sales estimate for the current quarter of $1.57 billion indicates a year-over-year change of +3.9%. For the current and next fiscal years, $6.8 billion and $7.77 billion estimates indicate +12.4% and +14.2% changes, respectively.

Last Reported Results and Surprise HistoryDraftKings reported revenues of $1.65 billion in the last reported quarter, representing a year-over-year change of +16.8%. EPS of $0.2 for the same period compares with $0.12 a year ago.

Compared to the Zacks Consensus Estimate of $1.64 billion, the reported revenues represent a surprise of +0.12%. The EPS surprise was -9.09%.

Over the last four quarters, DraftKings surpassed consensus EPS estimates times. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

DraftKings is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about DraftKings. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Dave & Buster's Entertainment (NASDAQ:PLAY) reported a steeper-than-expected drop in first-quarter profit and revenue as softer consumer sentiment and a marketing misstep weighed on comparable store sales.

The video game and restaurant chain posted adjusted earnings per share of $0.22 for the quarter, falling well short of the analyst consensus of approximately $0.90.

Revenue declined 1.5% year-over-year to $559.2 million, missing the $580.6 million expected by analysts.

Comparable store sales fell 5.4% in the quarter, significantly worse than the consensus estimate of a 1.2% decline. The company attributed the shortfall to macroeconomic headwinds including elevated gas prices and geopolitical uncertainty, as well as promotional tests that failed to connect with cost-conscious consumers.

Despite the weak headline results, management pointed to early signs of stabilization. Quarter-to-date comparable sales through mid-June were running at negative 4%, and the company said it expects to return to positive comparable sales for the remainder of fiscal 2026, beginning in mid-June, driven by a new games lineup, World Cup activations and a revitalized loyalty program with personalized offers.

The company also cited momentum in its food and beverage segment, where comparable sales rose 5% year-over-year for the ninth consecutive month of positive growth, and in special events, which saw a 3% comparable sales gain.

On the operational side, Dave & Buster's reported a meaningful swing in adjusted free cash flow, improving to positive $25.3 million from negative $58.8 million in the prior year period. Management reiterated its fiscal 2026 target of generating more than $100 million in free cash flow, with approximately $499 million in total liquidity.

Dave & Buster's also reported continued international expansion, opening its fifth and sixth franchise locations in May and June 2026, including a partnership to develop 15 venues in India.

Jefferies analysts said they view risk/reward as skewed to the upside at current valuations.

The firm noted the stock trades at roughly 4 times estimated 2027 EBITDA, a discount to most full-service peers at 5 to 12 times.

The bank lowered its 2026 comparable sales estimate to negative 2.4% and cut its adjusted EBITDA forecasts for 2026 and 2027 to $433 million and $469 million, respectively.

Shares opened about 2.6% lower on Tuesday.

Dave & Buster’s stock is among today’s weakest performers. What’s pressuring PLAY stock? Earnings HighlightsDave & Buster’s reported adjusted earnings per share of 22 cents, missing the consensus estimate of 61 cents. In addition, it reported revenue of $559.20 million, missing the consensus estimate of $580.46 million and representing a 1.5% year-over-year decline.

Comparable store sales fell 5.4% compared to the same period in fiscal 2025. The company ended the quarter with $499.1 million in available liquidity.

Dave & Buster’s opened one new domestic store in the first quarter and three additional domestic stores in the second quarter. The company has completed six store remodels in fiscal 2026 and expects two more by year-end. Its international franchise footprint expanded to six stores with openings in May and June.

“While first quarter results fell short of expectations, our back-to-basics strategy is gaining clear traction,” said Tarun Lal, CEO. “We are highly confident in our ability to drive positive comps for the remainder of the year while generating over $100 million in free cash flow in fiscal 2026.”

Analyst Consensus & Recent ActionsThe stock carries a Hold rating with an average price target of $14.67. Recent analyst moves include:

UBS: Neutral (Lowers Target to $12.00) (June 16) Dave & Buster’s Shares CraterPLAY Price Action: At the time of publication, Dave & Buster’s shares are trading 18.02% lower at $10.10, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

-

Includes all-new Marvel Infinity Comics series and access to expansive digital catalog of comics

New York, NY--(BUSINESS WIRE)--USA TODAY PLAY, a unified digital hub for casual entertainment and gaming, part of USA TODAY Co., Inc. (NYSE: TDAY), announced a collaboration with Marvel Comics to provide an exclusive vertically-formatted Marvel Infinity “Spider-Man TODAY” Comic series to USA TODAY PLAY. The all-new specially created comic “Spider-Man TODAY” weekly subscriber series written by Al Ewing and illustrated by Todd Nauck will publish every Wednesday for the next 47 weeks showcasing the adventures of the web-slinger teaming up with heroes from across the Marvel Universe.

Additionally, USA TODAY PLAY subscribers can enjoy unlimited access to a catalog of 1,000 digital comics from Marvel’s expansive breadth of characters and storylines including X-Men, Captain America, Black Panther, Fantastic Four, Guardians of the Galaxy, and Captain Marvel among many others. *Non-subscribers can explore a curated weekly selection.

“We’re thrilled to expand the USA TODAY PLAY brand through this exciting collaboration with Marvel,” said Dara Sanderson, Vice President and General Manager of USA TODAY PLAY. “We’re continuing to broaden our offerings, and this project is a testament to that. By blending iconic storytelling with interactive experiences true to the USA TODAY PLAY ethos, we continue to create daily moments that provide users well-deserved breaks from everyday stressors.”

“As digital comics continue to grow, we have the opportunity at Marvel to bring our comics to more fans across different platforms,” said Jon-Michael Ennis, Director of Digital Publishing at Marvel. “We’re excited to be working with USA TODAY to invite even more people to experience our comic book storytelling, whether they’re brand new to comics or lifelong readers.”

Featuring digital comics, puzzles, games and more, USA TODAY offers multiple ways to PLAY. Users can access content ad-free with a subscription, or for free using an ad-supported option. Paid subscribers also enjoy additional benefits, including unlimited hints and reveals in puzzles, full access to archival content, and early access to select new features.

*Subscription Pricing and Availability (subject to applicable terms and conditions)

USA TODAY PLAY monthly subscription: $0.99 for the first month, then $4.99 per month USA TODAY PLAY annual subscription: $39.99 per year Add USA TODAY PLAY monthly subscription to an existing USA TODAY Network subscription: $2 per month Add USA TODAY PLAY annual subscription to an existing USA TODAY Network subscription: $24 per year Anonymous Users: Enjoy access to 1 free Marvel comic a week (from a curated selection of 10) Registered Users: Enjoy access to 2 free Marvel comics a week (from a curated selection of 10) ABOUT USA TODAY CO., INC.

USA TODAY Co., Inc. is a diversified media company with expansive reach at the national and local level dedicated to empowering and enriching communities. Our mission is to inspire, inform, and connect audiences. As a media and digital marketing solutions company we are focused on sustainable growth. Through our trusted brands, including the USA TODAY NETWORK, comprised of the national publication, USA TODAY, and our network of local properties, in the United States, and Newsquest, a wholly-owned subsidiary operating in the United Kingdom, we provide essential journalism, local content, and digital experiences to audiences and businesses. We deliver trusted unbiased journalism when and where consumers want it. LocaliQ, our digital marketing solutions brand, supports small and medium-sized businesses with innovative digital marketing products and solutions.

ABOUT USA TODAY

Since its introduction in 1982, USA TODAY has been a cornerstone of the national media landscape under its recognizable and respected brand. It also serves as the foundation for our newsroom network which allows for content sharing capabilities across our local and national markets. Through USA TODAY, we deliver high-quality, trusted content with a commitment to balanced, unbiased journalism, where and when consumers want to engage. Across our digital platforms we reach an audience of approximately 87 million unique visitors each month (based on December 2025 Comscore Media Metrix®).

ABOUT MARVEL

Marvel is one of the world’s most prominent entertainment brands, built on an unparalleled library of iconic characters and stories that have shaped pop culture for over 85 years. The Marvel brand spans entertainment, including film, television, publishing, licensing, games, live events, digital media, and more. For more information visit marvel.com. © 2026 MARVEL

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that relate to our current expectations and views of future events. All statements other than statements of historical facts contained in this press release, including statements relating to whether this initiative will enable USA TODAY Co. to increase sales or revenues, beliefs, intentions, estimates or strategies regarding the future, which may not be realized. In some cases, you can identify forward-looking statements by terms such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” “could,” “will,” “would,” “ongoing,” “future” or the negative of these terms or other similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements involve known and unknown risks, uncertainties, contingencies, changes in circumstances that are difficult to predict and other important factors that may cause our actual results, performance, or achievements to be materially and/or significantly different from any future results, performance or achievements expressed or implied by the forward-looking statement. For a discussion of some of the risks and important factors that could cause actual results to differ materially from our expectations, see the risks and other factors detailed in “Item 3. Key Information - Risk Factors” in USA TODAY Co.’s (fka Gannett Co., Inc.) 2025 Annual Report on Form 10-K and USA TODAY Co.’s (fka Gannett Co., Inc.) quarterly reports on Form 10-Q and USA TODAY Co.’s (fka Gannett Co., Inc.) other filings with the SEC, in each case as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. USA TODAY Co. disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

More News From USA TODAY Co., Inc.

Back to Newsroom

Dave and Buster's Entertainment Inc. (NASDAQ:PLAY) reported downbeat earnings for the first quarter after the closing bell on Monday.

The company posted quarterly earnings of 22 cents per share, which missed the analyst consensus estimate of 61 cents per share. The company reported quarterly sales of $559.200 million, which missed the analyst consensus estimate of $580.461 million.

Dave and Buster's shares fell 8.8% to trade at $11.23 on Tuesday.

These analysts made changes to their price targets on Dave and Buster's following earnings announcement.

UBS analyst Dennis Geiger maintained the stock with a Neutral and lowered the price target from $13 to $12. BMO Capital analyst Andrew Strelzik maintained the stock with an Outperform rating and lowered the price target from $24 to $22. Benchmark analyst Mike Hickey downgraded Dave & Buster’s from Buy to Hold. Considering buying PLAY stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Dave & Buster's PLAY is experiencing significant pressure after falling short of expectations in its Q1 (April) report. The company reported a notable EPS miss, with revenue declining 1.5% year-over-year to $559.2 million. The primary concern appears to be a drop in customer traffic, particularly during the peak spring break season in March and April, attributed to macroeconomic pressures and declining consumer sentiment. However, management pointed to improving free cash flow, positive trends in food and beverage sales, and strong performance from remodeled locations as indicators that internal changes are beginning to take effect.

Traffic and Food & Beverage Performance: Same-store sales fell by 5.4%, worsening from a 3.3% decline in Q4 (January). On a positive note, food and beverage comps increased by approximately 5%, marking nine consecutive months of growth in this area, indicating that the main issue lies with entertainment traffic. Challenges: The company's $1-per-day promotional messaging did not resonate as intended, compounded by macroeconomic pressures and weaker consumer sentiment during March and April. Although Q2-to-date comps have improved, they remain down about 4%. Successful Remodels: The remodeled locations have outperformed the overall system by nearly 700 basis points. Management noted that the new prototype remodels cost about half of the previous versions while delivering a 7% comp uplift. Traffic Recovery Initiatives: PLAY is working to boost traffic through a marketing reset, new promotions, fresh game offerings, World Cup activations, and value deals like Eat & Play bundles. The company recently introduced 10 new games and anticipates adding at least five more this year. Capital Allocation Strategy: PLAY plans to open 11 new stores in FY26 but has expressed a willingness to allocate more capital towards remodels and core business improvements. Future openings in FY27 and FY28 may slow to around five per year. Future Outlook: The company is still targeting positive comps for the remainder of FY26, along with EBITDA growth and over $100 million in free cash flow. Analysts note that this was not the anticipated start for PLAY or its investors as the company navigates its turnaround. Comp sales have declined in Q1, and while macroeconomic headwinds impacted the busy spring break season, the execution of the promotional strategy also fell short. Although improvements in food and beverage trends, successful remodels, and enhanced free cash flow indicate some internal progress, they have not sufficiently countered the decline in traffic and entertainment revenue. With Q2-to-date comps still down about 4%, it remains challenging to support management's goal for positive comps for the rest of FY26. Until PLAY demonstrates a recovery in traffic and entertainment revenue, investor skepticism regarding the turnaround may persist, despite the positive signs from remodels and cash flow.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Dave & Buster's Entertainment PLAY shares fell about 4% after the company reported weaker-than-expected fiscal first-quarter 2026 results, as softer customer demand and higher operating costs weighed on sales and profitability.

The restaurant and entertainment operator posted adjusted earnings per share of $0.22, missing analysts' consensus estimate of $0.37.

The figure also declined significantly from adjusted earnings of $0.76 per share reported in the year-ago quarter.

Revenue totaled $559.2 million, falling short of Wall Street expectations of approximately $571 million and declining 1.5% from the prior year.

The company said lower comparable-store sales contributed to the revenue decline, partially offset by growth from newer locations.

The quarter was marked by weaker traffic at existing locations, particularly within the company's higher-margin entertainment business.

Comparable-store sales, including Main Event-branded locations, declined 5.4% year over year.

Management attributed the decline largely to reduced walk-in traffic compared with the same period last year.

The weakness came despite continued efforts to improve customer engagement through promotional initiatives and operational enhancements.

Dave & Buster's Chief Executive Officer, Tarun Lal, said the company entered the quarter with positive momentum before broader economic conditions affected consumer behavior.

“Of the macro backdrop, elevated gas prices, geopolitical uncertainty and a meaningful softness in consumer sentiment. They all were a real headwind in April.”

The softer demand environment weighed on discretionary spending, affecting both customer visits and overall sales trends during the quarter.

Performance varied significantly across business segments.

Food and beverage revenue increased 6.5% year over year to $214.1 million, supported by menu updates and enhancements to the company's eat-and-play combo offerings introduced during the second half of fiscal 2025.

The company said these initiatives helped improve food attachment rates and average customer spending.

However, entertainment revenue declined 5.9% year over year to $345.1 million.

Since arcade and gaming operations typically generate higher margins than food and beverage sales, the shift in revenue mix created additional pressure on profitability.

Management also reviewed the effectiveness of its marketing efforts during the quarter.

“We found that our dollar per day messaging did not resonate as strongly as we hoped. And since then, we have pivoted to more compelling promotions, which are resonating with customers,” said Lal.

The company said it has since adjusted its promotional strategy in an effort to better connect with value-conscious consumers.

Profitability weakened during the quarter as lower sales leverage combined with higher expenses.

Operating income declined to $46.9 million from $63.2 million a year earlier. Operating margin fell to 8.4% from 11.1%.

Adjusted EBITDA totaled $123.2 million, down from $136.1 million in the prior-year quarter. Adjusted EBITDA margin contracted to 22% from 24%.

Despite the disappointing results, management highlighted progress in several areas of its turnaround strategy.

The company said improvements to food and beverage offerings, marketing initiatives, and its remodel program are helping enhance the guest experience.

Dave & Buster's also continued to invest in future growth through new store openings, remodel projects, and international franchise expansion.

Management indicated that these initiatives remain central to its long-term strategy despite near-term challenges from a cautious consumer environment.

Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY

Visit Vote.Vaxart.com for Additional Information and Voting Resources

SOUTH SAN FRANCISCO, Calif., June 16, 2026 (GLOBE NEWSWIRE) --  Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders from the Board’s two newest independent directors, James Breitmeyer, M.D., Ph.D., and Kevin Finney, urging them to vote “FOR” ALL six of the company’s highly qualified director nominees on the WHITE proxy card in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.

The full text of the letter is as follows:

Dear Fellow Shareholders,

We are Vaxart’s two newest independent directors, having each joined the Board in the last 18 months. We’d like to take this opportunity to explain why we both believe your vote on the WHITE proxy card “FOR” ALL of Vaxart’s directors before the July 16th Annual Meeting is essential.

Between us, we have spent more than 70 years in biotechnology, with expertise spanning clinical development, regulatory strategy, financing, business development and executive leadership. We joined the Board with the explicit purpose of providing fresh perspectives and open minds. We did not come to this Boardroom with preconceived notions or established relationships with Vaxart’s other directors.

We view our roles as the newest members to critically evaluate and review the Company’s current strategy. We are leveraging our respective experiences and very high expectations to hold management accountable for the Company’s performance and execution of its strategy.

Our time on the Board has reinforced that this is a team committed to creating shareholder value. Vaxart is on the brink of unlocking the value of years of scientific innovation. But there is much more work that needs to be done. This is not the time to disrupt a Board that has the experience, independence and judgment to oversee the path forward.

We recommend that shareholders vote on the WHITE proxy card “FOR” ALL 6 of Vaxart’s directors.

Our Board is Driving Vaxart Forward and Holding Management Accountable

Since we joined Vaxart, it has been clear to us that this Board is active, informed and willing to change when needed. Each of the Board’s members brings important and relevant skills to the table and plays an active role in steering the Company to success. Our Board discussions are frequent and substantive. Management is pushed. Alternatives are considered. Decisions are evaluated through the lens of clinical progress, capital discipline, strategic opportunity and long-term shareholder value.

The directors at the center of this election – Steven Lo, Dr. Elaine J. Heron and Dr. David Wheadon – all bring experience that is directly relevant to Vaxart’s needs today: proven life sciences and drug development track records, public company and operational leadership, and decades of clinical research and regulatory experience. Those perspectives are not theoretical.

Removing these directors and replacing them with unqualified nominees would immediately undermine the Company’s ability to bring informed, experienced judgment to the decisions that matter most for Vaxart’s future and to advance critical government and commercial relationships that are essential to success.

Vaxart Leadership is Successfully Navigating a Difficult Macro and Industry Environment

Like many other companies in our industry, Vaxart has faced macro challenges beyond any individual company’s control, including the stop-work orders BARDA issued across many vaccine programs in early 2025. This Board responded decisively, working with management to secure funding for the ongoing Phase 2b COVID-19 study, strengthening Vaxart’s financial position through the Dynavax partnership, streamlining operations and extending the Company’s runway.

These were consequential actions taken to preserve Vaxart’s opportunity to operate. In our view, they demonstrate the kind of oversight and action Vaxart needs: engaged, pragmatic and made possible because of the specific experience and expertise our Board and management team bring to the table. Our CEO, Steven Lo, has been instrumental in all of these efforts. We fully endorse his leadership, and we believe that the actions he has taken have been essential to keeping the Company in business and on a path to realizing the value of our pipeline.

We have seen that same discipline and sense of purpose inside the Company. Recently, Jim spent time with members of Vaxart’s research and development organization. The conversations were candid, data-driven and grounded in a realistic understanding of Vaxart’s opportunities and challenges. The excitement is palpable and we are full steam ahead.

Vote the WHITE Proxy Card Today

Vaxart needs directors who understand the Company at every level and who can apply that knowledge to our future. The current Board brings that exact combination of relevant expertise, Company-specific context and accountability to shareholders. With important clinical and operational milestones ahead, continuity of experienced oversight matters. Focus matters. Avoiding unnecessary disruption matters.

A group of dissident shareholders is seeking to add themselves to the Board and replace half of Vaxart’s directors. These dissident nominees have claimed that Vaxart needs directors who bring stronger oversight and greater accountability. That is not our experience. And the dissident nominees are certainly not the people who will advance our programs, strengthen our partnerships or ensure Vaxart has the financial resources to achieve its goals in this environment.

We joined this Board because we believe in Vaxart’s mission and its potential. We are committed to taking the actions necessary and to holding management’s feet to the fire, so we can bring Vaxart’s important vaccines to market and create value for shareholders.

Join us in voting “FOR” ALL 6 of the Company’s highly qualified director nominees on the WHITE proxy card TODAY. Thank you for your continued support.

Sincerely,

James B. Breitmeyer, M.D., Ph.D., and Kevin P. Finney

Vote “FOR” ALL 6 of Vaxart’s highly qualified director nominees on the WHITE proxy card TODAY!

If you have questions or require assistance with voting your shares, please call Vaxart’s proxy solicitor:

Campaign Management, LLC
Toll-Free: +1 (855) 264-1527

Additional shareholder resources and voting information can be found at Vote.Vaxart.com.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Cautionary Language Concerning Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” provisions created by those sections, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this communication regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” “target,” “seek,” “intend,” “may,” “predict,” “project,” “would,” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; and Vaxart’s expectations with respect to the effectiveness of its product candidates; expectations regarding collaborations, including the collaboration with Dynavax; expectations regarding the pursuit of strategic partnerships and external funding opportunities for Vaxart’s programs; expectations regarding government funding; and expectations regarding Vaxart’s capital resources and funded runway. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K, including amendments thereto, and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Important Additional Information and Where to Find It

 Vaxart has filed a definitive proxy statement and form of white proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Stockholders are able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at https://investors.vaxart.com/financials-filings/sec-filings.

Investor Contact

Michael Fein
Campaign Management
(855) 264-1527

Media Contact

Aaron Palash / Adam Pollack
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Part 1 of this article compares RITM's recent investment composition, leverage, hedging coverage ratio, quarterly BV, economic return (loss), and current valuation to 17 mREIT peers. Due to what has occurred during Q2 2026 (fluctuating rates/yields), understanding the composition of RITM's MSR/investment and derivatives portfolio is crucial in understanding current/future performance. My current RITM BV projection and updated price target is in the “Conclusions Drawn” section. RITM is currently deemed notably undervalued (strong buy recommendation).

In the latest close session, Sirius XM (SIRI - Free Report) was up +1.46% at $27.86. The stock outpaced the S&P 500's daily loss of 0.57%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq decreased by 1.15%.

Shares of the satellite radio company witnessed a gain of 5.25% over the previous month, beating the performance of the Consumer Discretionary sector with its gain of 2.7%, and the S&P 500's gain of 2.14%.

Investors will be eagerly watching for the performance of Sirius XM in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.78, reflecting a 36.84% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.14 billion, up 0.11% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $3.1 per share and a revenue of $8.56 billion, indicating changes of -2.82% and +0.02%, respectively, from the former year.

Investors should also note any recent changes to analyst estimates for Sirius XM. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Sirius XM is currently a Zacks Rank #3 (Hold).

Investors should also note Sirius XM's current valuation metrics, including its Forward P/E ratio of 8.85. This valuation marks a discount compared to its industry average Forward P/E of 12.69.

It is also worth noting that SIRI currently has a PEG ratio of 0.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Broadcast Radio and Television was holding an average PEG ratio of 1.04 at yesterday's closing price.

The Broadcast Radio and Television industry is part of the Consumer Discretionary sector. This industry, currently bearing a Zacks Industry Rank of 109, finds itself in the top 45% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.